Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a placebo and colesevelam. Colesevelam is a bile acid sequestrant used primarily to lower elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia and to improve glycemic control in adults with type 2 diabetes mellitus. It works by binding bile acids in the intestine, preventing their reabsorption, which leads to increased conversion of cholesterol into bile acids and upregulation of LDL receptors, thereby lowering blood LDL cholesterol levels. Placebo is an inactive substance used as a control in clinical trials and has no therapeutic effect[2][4][6]. This combination may be used as part of clinical studies comparing the effects of colesevelam versus placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + colesevelam.